Dear readers of ADxS.org, please forgive the disruption.

ADxS.org needs about $53200 in 2024. In 2023 we received donations from third parties of about $ 32200. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2024 would be over after a few days. This donation request is displayed 19,000 times a week, but only 40 people donate. If you find ADxS.org useful, please take a minute and support ADxS.org with your donation. Thank you!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V..

$3391 of $53200 - as of 2024-02-01
6%
Header Image
ADHD animal models with unknown dopamine alteration

Sitemap

ADHD animal models with unknown dopamine alteration

In this article, we collect animal models for ADHD in which the way in which dopamine levels change has not yet been revealed to us.

3. Animal models with unchanged or (to us) unknown dopamine changes

3.1. 39.XY*O–Mouse (DHEA deficiency) (dopamine unchanged)

39,XY*O mice are genetically unable to produce steroid sulfatase (STS). Among other things, STS breaks down the steroid DHEAS.

39,XY*O mice showed compared to 40,XY mice:1

  • increased reactivity to a new environment1
  • Hyperactivity in the active phase1
  • Inattention2
  • increased emotional reactivity1
  • increased water consumption (but not food)1
  • increased motivation2
  • no difference in social dominance1
  • significantly lower DHEA serum levels1
  • equivalent corticosterone levels1
  • Increased serotonin2
    • in the striatum
    • in the hippocampus
  • Reduced serotonin turnover2
    • in the striatum
    • in the hippocampus
  • Noradrenaline turnover reduced2
    • in the striatum
  • MOPEG decreases in the striatum2
  • Dopamine unchanged in PFC, striatum, hippocampus, thalamus, cerebellum2

The STS gene is a gene candidate for ADHD.

3.2. GIT1-KO mouse (dopamine effect reduced?)

The G-protein coupled receptor kinase 1 knockout mouse (GIT1-KO) serves as an animal model for research into ADHD.34
The GIT1 KO mouse shows symptoms of ADHD:5

  • Hyperactivity
    • remediable with amphetamine and methylphenidate
  • Learning disorders
  • Memory loss

GIT1 regulates dopamine receptors. Overexpression of GIT1 interferes with the internalization of numerous G-protein-coupled receptors, including dopamine receptors.6 The latter suggests a model of reduced dopamine action.
GIT1 is a candidate gene for ADHD.

3.3. ATXN7 Overexpressed mouse

The ATXN7 Overexpressed mice (ATXN7-OE) show

  • Hyperactivity
  • Impulsiveness
  • no inattention

Dires corresponds to the ADHD-HI subtype.
The ataxin 7 gene (ATXN7) correlates with hyperactivity. ATXN7-OE mice have overexpression of the Atxn7 gene and protein in the PFC and striatum. Atomoxetine (3 mg/kg, intraperitoneal) reduces ADHD-HI-like behavior and ATXN7 gene expression in the PFC and striatum.7

3.4. Grin1 mouse

Grin1 mice are a heterozygous mutant strain. Grin1 (Glutamate [NMDA] receptor subunit zeta-1) encodes a protein required for NMDA receptor function. Grin2B may be associated with ADHD. Grin1 mice show:

  • Hyperactivity8
  • Novelty seeking8
  • Reduced social interaction8
  • Anxiety9

The attentional abilities of Grin1 mice have not yet been investigated.8

Hyperactivity improved with high-dose methylphenidate. While c-FOS was very low in the prelimbic cortex and striatum of control mice and increased by MPH, c-FOS was high in the prelimbic cortex of GRIN1Rgsc174 ⁄ + mice and was reduced by MPH (at very high doses). Grin1Rgsc174 ⁄ + mice further showed increased phosphorylation of the protein ERK2 in the nucleus accumbens, which hardly changed even after a very extreme MPH dose (30 mg/kg). The authors concluded that the behavioral symptoms of the GRIN1 mouse were due to NMDA receptor dysfunction in the relevant brain regions, and that the effect of MPH in the GRIN1 mouse was not specifically mediated via the DAT but via other receptors or influences, since the DAT should have shown an effect even at much lower doses.9 The authors also point to the altered glutamatergic neurotransmission in SHR. SHR do not react at all to MPH with regard to hyperactivity, but do respond to AMP (see there).

3.5. AGCYAP1-KO mouse

The Adcyap1 gene encodes the neuropeptide Adenylate Cyclase Activating Polypeptide 1 generated in the pituitary gland. Mice lacking the ADXAP1 gene (Adcyap1(-/-)) show increased novelty seeking and hyperactivity. One study found sensory-motor gating deficits in them in the form of prepulse inhibition (PPI) deficits. Amphetamine was able to normalize PPI and hyperactivity. This occurred via serotonin 1A (5-HT(1A)) receptor signaling. Wild-type mice also developed hyperactivity in response to the 5-HT(1A) agonist 8-hydroxy-2-(di-n-propylamino)tetralin, which was also reversed by AMP. In addition, increased c-Fos-positive neurons were found in the PFC of AGCYAP1-KO mice treated with AMP, indicating increased inhibitory control by prefrontal neurons.10

3.6. TACR1-KO mouse

The Neurokinin-1 (Substance P, Tachikinin) Receptor Knockout Mouse (TACR1-KO mouse) is another rodent model for ADHD.11

Virtually all dopaminergic neurons of the substantia nigra pars compacta and many of the substantia nigra pars reticulata contained neurokinin-1 receptors.12 Substance P mediates its effect via postsynaptic heteroreceptors as well as via presynaptic autoreceptors. Substance P has an excitatory effect and modulates the inhibitory effect of GABA in the substantia nigra.
Substance P is involved in the regulation of dopamine release in the striatum.1314 The effect of substance P on dopaminergic transmission appears to be mediated by a nigro-thalamo-cortico-striatal loop.15
Substance P increases dopamine in the nucleus accumbens, but not in the neostriatum.16
TACR1 is associated with dopaminergic activity in the striatum.17 TACR1 mediates the action of protein kinase C pathway in the downregulation of DAT and NET. The effect appears to be mediated via NET rather than DAT.18

We believe that these data may be indicative of reduced dopamine levels in TACR1-KO mice.

3.7. Guanylylcyclase-C-KO mouse (GC-C-KO mouse)

Guanylyl cyclase-C (GC-C) is a membrane receptor and is found together with tyrosine hydroxylase in the VTA and the substantia nigra pars compacta. GC-C can modulate dopamine signaling. Activation of GC-C by GC-C ligands, such as guanylin or uroguanylin, potentiates the excitatory responses mediated by glutamate and acetylcholine receptors via the activity of guanosine 3’,5’-monophosphate-dependent protein kinase (PKG), which affects dopaminergic cells.

GC-C-KO mice show:

  • Hyperactivity (?)
    • in familiar and new environments19
    • is canceled by
      • systemic AMP injection19
      • GMP-dependent protein kinase agonist infusions into the VTA19
    • Another study found no hyperactivity20
  • Attention deficit in the Go/No-Go test.19
    • is canceled by
      • systemic AMP injection19
      • GMP-dependent protein kinase agonist infusions into the VTA19
  • extensive investigation of new odors19
  • Recognition of new objects impairs20
  • tactile shock reduces20
  • acoustic shock unchanged20
  • increased latency during training trials in the Morris water maze only in females20
    • not for spatial learning attempts with a hidden platform

3.8. GAT1-KO mouse

Tonic GABA inhibits the release of dopamine in the striatum (of the mouse) via GABA-A and GABA-B receptors. Only a few GABA-ergic synapses are present at the dopamine axons. Therefore, the tonic inhibition of dopamine release by striatal GABA is probably mediated by extrasynaptic effects of extracellular GABA on receptors presumably located on dopamine axons. GABA therefore shows extrasynaptic effects on other neurons.
The gamma-aminobutyric acid transporter subtype 1 and subtype 3 reabsorbs GABA. If the GABA transporters GAT1 or GAT3 are reduced or switched off, this increases the extracellular GABA and thus reduces the release of dopamine in the dorsal striatum, but not in the nucleus accumbens.2122

The two isoforms of the GAT in the striatum are:

  • GAT-1 (Slc6a1)
    • common in axons of GABA-ergic neurons
    • in striatal astrocytes
    • in DA midbrain neurons
    • on striatal DA axons
  • GAT-3 (Slc6a11)
    • moderately expressed
    • especially occurring on (striatal) astrocytes
      • Dysregulation of GAT-3 on striatal astrocytes causes profound changes in SPN activity and striatal-driven behavior through decreased extralellular dopamine23
    • in DA midbrain neurons
    • on striatal DA axons

(GAT1)-KO mice (GAT-1-/- mice) show typical ADHD symptoms:2425

  • Hyperactivity
    • AMP and MPH reduce these
  • motor problems
    • Ataxia, characterized by deficiencies in motor coordination and balance
  • Attention problems
    • Impairment of attentional focus in an “incentive runway test”
  • Impulsiveness in an incentive test for passive avoidance
  • Memory problems
    • Deficits in spatial reference memory

3.9. TR-beta 1 transgenic mouse

Carries a mutated human thyroid receptor TRb 1 gene.

TRbeta-transgenic mice26

  • are euthyroid except for a short period during postnatal development (= normal thyroid hormone levels of triiodothyronine (T3) and thyroxine (T4)).
  • show until adulthood
    • Changes in the dopaminergic system (increased dopamine turnover)
    • ADHD symptoms
    • paradoxical reaction to MPH

Thus, like the vast majority of children with ADHD, the TRbeta transgenic mice show ADHD symptoms without measurable thyroid abnormalities. It is possible that even transient disturbances in developmental thyroid homeostasis cause long-lasting behavioral and cognitive consequences, including the development of the full spectrum of ADHD symptoms.

Symptoms:

  • Hyperactivity
  • Impulsiveness
  • Inattention
  • All symptoms
    • Are reduced by methylphenidate
    • As with ADHD, are dynamic and react sensitively to changing environmental conditions, stress and reinforcement

3.10. FEZ1-KO mouse

The Fez1 gene (fasciculation and elongation protein zeta-1) is specifically expressed in the nervous system and is involved in neurodevelopment.
FEZ1 knockout mice show:27

  • Hyperactivity28
  • Impulsiveness
  • Tyrosine hydroxilase expression reduced in midbrain and brainstem
  • Dopamine and noradrenaline levels and their metabolites in the nucleus accumbens and PFC reduced
  • MPH and guanfacine caused
    • Hyperactivity and impulsivity improved
    • Dopamine and noradrenaline levels restored in the nucleus accumbens and PFC
    • Tyrosine hydroxilase expression increased

The FEZ1 gene is specifically expressed in the nervous system and is most strongly expressed during neurodevelopment [21]. FEZ1 is involved in various processes of neurodevelopment, such as:27

  • Neurite extension
  • dendritic arborization
  • axonal transport
  • neuronal migration

3.11. STA3GAL5(-/-) - Mouse

St3gal5-/- mice. In contrast to B4galnt1-/- mice, the clinical abnormalities only partially regress in these mutants, which could be due to the compensatory synthesis of the 0-series gangliosides GD1α and GM1b. However, the
St3gal5-/- mice lack the most important CNS gangliosides GM3, GM1, GD1a, GD3, GT1b and GQ1b
St3gal5-/- mice show:29

  • motor hyperactivity
  • Impulsiveness
  • Inattention30
  • increased insulin sensitivity31
  • autistic behavior32
    • conditioned taste aversion impaired in an inhibitory learning task
    • fear-like behavior in the field
    • motor deficits (moderate)
    • abnormal social interactions
    • excessive grooming and rearing behavior
  • Platelet activation and neuronal damage after traumatic brain injury
  • Proteolipid protein-1 (Plp1) gene and protein expression reduced32
  • proinflammatory cytokine expression increased32
    • Interleukin1β is upregulated
  • Lipopolysaccharides induce sex-dependent abnormalities in inflammatory response and social behavior32
  • Signs of hypomyelination32

The STA3GAL5-KO mouse is a mild form of the STA3GAL5 disorder.33 More severe forms are associated with developmental disorders, severe hearing, visual, motor and cognitive impairments as well as respiratory chain disorders. More on this at STA3GAL5 In the article Gene candidates without a plausible pathway in relation to ADHD

St3gal5-/-/B4galnt1-/- mice with double knockout lack any ganglioside derivative of LacCer.
Soon after birth, they develop severe neurodegeneration with impaired axon-glia interactions, weakness of the hind limbs, ataxia, tremor and increased inflammatory reactions. They die before the age of two months.34

3.12. PACAP(-/-) - Mouse

Mice with pituitary adenylate cyclase-activating polypeptide (PACAP) deficiency (PACAP(-/-)):35

  • Hyperactivity
  • Memory for new objects impaired
  • Pre-pulse inhibition impaired

Atomoxetine improved all 3 symptoms and increased extracellular norepinephrine and dopamine in the PFC of PACAP(-/-) mice more than in wild-type mice.

3.13. Wheelrunning mouse

Mice bred by selection of those animals with a higher voluntary use of the running wheel showed:3637

  • Hyperactivity in a new environment

  • more wheel utilization in the form of shorter and faster runs

  • Hyperactivity even after 24-hour acclimatization in cages without wheels

  • D1/D5 receptors with reduced function

  • D2/D3/D4 receptors unchanged

  • Cocaine (dopamine reuptake blocker)37

    • reduces average speed, but not duration of wheel use with wheel running mice
    • unchanged impeller use with wild type
  • GBR 12909 (dopamine reuptake blocker)37

    • reduces average speed, but not duration of wheel use with wheel running mice
    • unchanged impeller use with wild type
  • Ritalin (15 mg/kg and 30 mg/kg)36

    • reduced wheel usage with wheel running mice
    • increased wheel utilization with wild type
  • Apomorphine (non-selective D2 agonist)36

    • 0.125 mg/kg reduced wheel use in wheelrunning mice and wild-type mice alike
    • 0.25 mg/kg and 0.5 mg/kg reduced spawning wheel utilization in the wild type to a greater extent
  • SCH 23390 (selective D1/D5 antagonist)36

    • 0.025, 0.05 and 0.1 mg/kg reduced running wheel use in wild type more than in running mice
  • Racloprid (selective D2 antagonist)36

    • 0.5, 1 and 2 mg/kg reduced wheel use in wheelrunning mice and wild type to a similar extent
  • Fluoxetine (SSRI)37

    • reduced running speed and duration of wheel use in wheel-running mice and wild type proportional to baseline activity

3.14. Naples high-excitability rat (NHE)

The Naples high-excitability rat was selected based on increased exploration in a Làt-Maze.38

  • Permanent attention problems38
  • Hyperactive and impulsive in a new environment
  • Not hyperactive or impulsive in a familiar environment
  • NHE show hyperactivity in the field, but not in the home cage39(anders als SHR)38
  • NHE become more active with increasing environmental complexity40
  • Handling
    • Handling: young, unweaned animals are removed from the litter and mother for a few minutes each day and placed alone in an empty cage without any further manipulation. They are then returned to their mother and siblings41
      Barbara
    • light handling influences the activity of NHE rats differently than heavy handling42
    • Handling in the fifth and sixth week of life can reduce hyperactivity in SHR and normalize neuronal markers (DRD1, CAMKII, c-fos)38
  • Hyperdopaminergic innervation of the PFC with overexpression of mRNA species involved in basal metabolism40 (overactivated mesocorticolimbic system)
  • Downregulation of dopamine D1 receptors40
  • DAT increased38
    • Consequence of an excess of dopamine in early development
    • NHE have more dopamine-synthesizing endings, more dopamine and consequently more DAT
    • The midbrain DA neurons are hypertrophic and have more terminals expressing tyrosine hydroxylase.

3.15. PTCHD1-KO mouse

In the PTCHD1-KO mouse, the PTCHD1 receptors in the thalamus are deactivated.

Male mice with deactivated PTCHD1 showed:

  • Distractibility43
  • Problems with recognition memory44
    • Atomoxetine eliminated this change.44
  • Hyperactivity4344
    • Atomoxetine eliminated this change.44
  • Impulsiveness44
    • Atomoxetine eliminated this change.44
  • Learning disorders43
  • Hypotension43
  • Aggression43
  • Sleep fragmentation43

There were also changes in the kynurenine metabolism.44

When PTCHD1 was only deactivated in the reticular nucleus of the thalamus, only increased levels of43

  • Distractibility
  • Hyperactivity
  • Sleep problems

3.16. Neonatal anoxia mouse

Neonatal anoxia (postnatal oxygen deficiency) increases the risk of ADHD.4546

Symptoms:
Males were more severely affected than females.47

  • Hyperactivity
    • for males in the open field4849
    • from day P20 to P4550
    • not increased51
  • Permanent deficits in spatial memory5052
  • cognitive impairments during task acquisition51
  • Deficits in sustained attention51
  • Increased impulsivity51
  • Compulsiveness increased51
  • increased sensation of pain53
    • Gender-specific reactions depending on the nociceptive stimulus
  • Fear behavior in adult males47

Neurophysiological changes:

  • Anomalies with monoamines54
  • Changed cell density in the CA1 hippocampus50
  • Cell loss in substantia nigra55
  • Loss of brain volume, especially ipsilateral, in51
    • entire hemisphere
    • Cerebral cortex
    • white substance
    • Hippocampus
    • Striatum

Acute anoxia (acute lack of oxygen):54

  • Within 20 minutes:
    • Noradrenaline reduced in the cerebellum
    • Dopamine reduced in the striatum
    • 5-Hydroxyindoleacetic acid (5-HIAA) increased in the cortex and cerebellum
  • P7 (7th day)
    • Noradrenaline increase in the cerebellum
    • Serotonin (5-HT) and 5-HIAA reduced in the cortex and cerebellum
  • P21
    • Noradrenaline increase in the hippocampus
    • Increase in homovanillic acid (HVA) in the striatum
    • Serotonin decreases in the striatum
    • 5-HIAA increase in striatum and hippocampus
  • P60
    • 3,4-Dihydroxyphenylacetic acid (DOPAC) increased in striatum
    • and 5-HIAA levels increased in the striatum

15 minutes caused perinatal asphyxia (lack of oxygen during birth):56

  • Tyrosine hydroxylase mRNA levels increased in VTA and substantia nigra
  • DRD1 and DRD2 mRNA increased in the striatum

A similar mouse model, which simulates the damage of oxygen deprivation caused by extreme premature birth through repeated hypoxia, showed57

  • Hyperactivity and impulsivity as a reaction to a delayed reward
  • no hyperactivity in an unfamiliar environment
  • no inattention
  • significant specific loss of dopaminergic neurons (only) in the right VTA

3.17. Cry1Δ11 mice

Cry1Δ11 (c. 1717 + 3A > C) mice show ADHD-C-like symptoms:58

  • Hyperactivity
  • Impulsiveness
  • Learning deficits
  • Memory deficits
  • hyperactive cAMP signaling pathway in the nucleus accumbens
  • upregulated c-Fos, mainly localized in dopamine D1 receptor-expressing medium spiny neurons (DRD1-MSNs) in the NAc
  • increased neuronal excitability of DRD1-MSNs in the nucleus accumbens
  • the CRY1Δ11 protein, unlike the WT CRY1 protein, could not mechanistically interact with the Gαs protein and inhibit DRD1 signaling
  • the DRD1 antagonist SCH23390 normalized most ADHD-like symptoms

3.18. Pln-/-KO mice

Phospholamban is found at the protein level in the reticular nucleus of the thalamus. This has a major influence on vital neurological processes, including executive functions and the generation of sleep rhythms.

Pln-/- mice exhibit a higher number of littermates compared to their Pln+/+ littermates:59

  • Hyperactivity
  • reduced anxiety behavior
  • Deficits in spatial working memory
  • unchanged object localization memory
  • impaired object recognition memory
  • social exploration behavior / sociability / preference for new social territory unchanged

In contrast, ablation of phospholamban, which was limited to the reticular nucleus of the thalamus and did not affect peripheral PLN synthesis in cardiac muscles, skeletal muscles and smooth muscles, leads to:59

  • Hyperactivity
  • Increased impulsivity
  • unchanged anxiety behavior
  • unchanged spatial working memory
  • Waking phases shortened
  • REM sleep prolonged, especially in females
  • non-REM sleep extended
  • Attention unchanged

3.19. Dogs with ADHD

A study on dogs with ADHD behavior found relatively reduced blood dopamine and serotonin levels.60

3.20. Drosophila (fruit fly)

Research on Drosophila has shown that gene variants determine the behavior of Drosophila in response to unpleasant air blasts, for example.
Drosophila that showed a particularly prolonged hyperactive reaction to bursts of air had a specific mutation in the dopamine transporter gene, which is one of the most important candidate genes for ADHD.61 When these Drosophila were treated with cocaine, they calmed down more quickly.
The dopamine D1 receptor was essential for the learning behavior of Drosophila. Drosophila with an artificially silenced D1 receptor (throughout the brain) were unable to learn that a particular odor acted as a warning signal for a puff of air.62
If the D1 receptor gene was repaired exclusively in the brain region of the central complex, the Drosophila were no longer hyperactive, but were still unable to learn. If, on the other hand, the D1 receptor gene was only repaired in the brain region of the “mushroom body”, the ability to learn was restored, while the hyperactivity remained.61

After 60 generations, a Drosophila breeding line that was bred for sleep problems also showed considerable hyperactivity and increased sensitivity to environmental stimuli.63

77 % of human disease genes have homologs in Drosophila.64 Although the evolutionary tree of Drosophila and humans diverged 700 million years ago, the Drosophila brain is organized in three parts (forebrain, midbrain and hindbrain) like that of vertebrates and uses the same important neurotransmitters (dopamine, glutamate, GABA, homologues of adrenaline, noradrenaline and serotonin) as well as the corresponding enzymes, transporters and receptors.6566


  1. Trent S, Dennehy A, Richardson H, Ojarikre OA, Burgoyne PS, Humby T, Davies W (2012): Steroid sulfatase-deficient mice exhibit endophenotypes relevant to attention deficit hyperactivity disorder. Psychoneuroendocrinology. 2012 Feb;37(2):221-9. doi: 10.1016/j.psyneuen.2011.06.006. PMID: 21723668; PMCID: PMC3242075.

  2. Trent S, Cassano T, Bedse G, Ojarikre OA, Humby T, Davies W (2012): Altered serotonergic function may partially account for behavioral endophenotypes in steroid sulfatase-deficient mice. Neuropsychopharmacology. 2012 Apr;37(5):1267-74. doi: 10.1038/npp.2011.314. PMID: 22189290; PMCID: PMC3306888.

  3. Sontag, Tucha, Walitza, Lange (2010): Animal models of attention deficit/hyperactivity disorder (ADHD): a critical review. Atten Defic Hyperact Disord. 2010 Mar;2(1):1-20. doi: 10.1007/s12402-010-0019-x.

  4. Kim, Woo, Lee, Yoon (2017): Decreased Glial GABA and Tonic Inhibition in Cerebellum of Mouse Model for Attention-Deficit/Hyperactivity Disorder (ADHD). Exp Neurobiol. 2017 Aug;26(4):206-212. doi: 10.5607/en.2017.26.4.206.

  5. Won, Mah, Kim, Kim, Hahm, Kim, Cho, Kim, Jang, Cho, Kim, Shin, Seo, Jeong, Choi, Kim, Kang, Kim (2011): GIT1 is associated with ADHD in humans and ADHD-like behaviors in mice. Nat Med. 2011 May;17(5):566-72. doi: 10.1038/nm.2330. PMID: 21499268.

  6. Kim H, Kim JI, Kim H, Kim JW, Kim BN (2017): Interaction effects of GIT1 And DRD4 gene variants on continuous performance test variables in patients with ADHD. Brain Behav. 2017 Aug 1;7(9):e00785. doi: 10.1002/brb3.785. PMID: 28948080; PMCID: PMC5607549.

  7. Dela Peña, Botanas, de la Peña, Custodio, Dela Peña, Ryoo, Kim, Ryu, Kim, Cheong (2018): The Atxn7-overexpressing mice showed hyperactivity and impulsivity which were ameliorated by atomoxetine treatment: A possible animal model of the hyperactive-impulsive phenotype of ADHD. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jan 10;88:311-319. doi: 10.1016/j.pnpbp.2018.08.012.

  8. Palm, Uzoni, Simon, Fischer, Coogan, Tucha, Thome, Faltraco (2021): Evolutionary conservations, changes of circadian rhythms and their effect on circadian disturbances and therapeutic approaches. Neurosci Biobehav Rev. 2021 Jun 5;128:21-34. doi: 10.1016/j.neubiorev.2021.06.007. PMID: 34102148. REVIEW

  9. Furuse, Wada, Hattori, Yamada, Kushida, Shibukawa, Masuya, Kaneda, Miura, Seno, Kanda, Hirose, Toki, Nakanishi, Kobayashi, Sezutsu, Gondo, Noda, Yuasa, Wakana (2010): Phenotypic characterization of a new Grin1 mutant mouse generated by ENU mutagenesis. Eur J Neurosci. 2010 Apr;31(7):1281-91. doi: 10.1111/j.1460-9568.2010.07164.x. PMID: 20345915.

  10. Takamatsu, Hagino, Sato, Takahashi, Nagasawa, Kubo, Mizuguchi, Uhl, Sora, Ikeda (2015): Improvement of learning and increase in dopamine level in the frontal cortex by methylphenidate in mice lacking dopamine transporter. Curr Mol Med. 2015;15(3):245-52. doi: 10.2174/1566524015666150330144018. PMID: 25817856; PMCID: PMC5384353.

  11. Kantak (2022): Rodent models of attention-deficit hyperactivity disorder: An updated framework for model validation and therapeutic drug discovery. Pharmacol Biochem Behav. 2022 Mar 31;216:173378. doi: 10.1016/j.pbb.2022.173378. PMID: 35367465. REVIEW

  12. Lévesque M, Wallman MJ, Parent R, Sík A, Parent A (2007): Neurokinin-1 and neurokinin-3 receptors in primate substantia nigra. Neurosci Res. 2007 Mar;57(3):362-71. doi: 10.1016/j.neures.2006.11.002. PMID: 17134780.

  13. Gauchy C, Desban M, Glowinski J, Kemel ML (1996): Distinct regulations by septide and the neurokinin-1 tachykinin receptor agonist [pro9]substance P of the N-methyl-D-aspartate-evoked release of dopamine in striosome- and matrix-enriched areas of the rat striatum. Neuroscience. 1996 Aug;73(4):929-39. doi: 10.1016/0306-4522(96)00099-1. PMID: 8809812.

  14. Khan S, Brooks N, Whelpton R, Michael-Titus AT (1995): Substance P-(1-7) and substance P-(5-11) locally modulate dopamine release in rat striatum. Eur J Pharmacol. 1995 Aug 25;282(1-3):229-33. doi: 10.1016/0014-2999(95)00342-i. PMID: 7498281.

  15. Baruch P, Artaud F, Godeheu G, Barbeito L, Glowinski J, Chéramy A (1988): Substance P and neurokinin A regulate by different mechanisms dopamine release from dendrites and nerve terminals of the nigrostriatal dopaminergic neurons. Neuroscience. 1988 Jun;25(3):889-98. doi: 10.1016/0306-4522(88)90042-5. PMID: 2457187.

  16. Huston JP, Hasenöhrl RU, Boix F, Gerhardt P, Schwarting RK (1993); Sequence-specific effects of neurokinin substance P on memory, reinforcement, and brain dopamine activity. Psychopharmacology (Berl). 1993;112(2-3):147-62. doi: 10.1007/BF02244906. PMID: 7532865.

  17. Humpel C, Saria A (1993): Intranigral injection of selective neurokinin-1 and neurokinin-3 but not neurokinin-2 receptor agonists biphasically modulate striatal dopamine metabolism but not striatal preprotachykinin-A mRNA in the rat. Neurosci Lett. 1993 Jul 23;157(2):223-6. doi: 10.1016/0304-3940(93)90742-4. PMID: 7694197.

  18. Mannangatti P, Ragu Varman D, Ramamoorthy S, Jayanthi LD (2021): Neurokinin-1 Antagonism Distinguishes the Role of Norepinephrine Transporter from Dopamine Transporter in Mediating Amphetamine Behaviors. Pharmacology. 2021;106(11-12):597-605. doi: 10.1159/000518033. Epub 2021 Sep 2. PMID: 34515205; PMCID: PMC8578286.

  19. Gong R, Ding C, Hu J, Lu Y, Liu F, Mann E, Xu F, Cohen MB, Luo M (2011): Role for the membrane receptor guanylyl cyclase-C in attention deficiency and hyperactive behavior. Science. 2011 Sep 16;333(6049):1642-6. doi: 10.1126/science.1207675. PMID: 21835979.

  20. Mann EA, Sugimoto C, Williams MT, Vorhees CV (2019): Mouse knockout of guanylyl cyclase C: Recognition memory deficits in the absence of activity changes. Genes Brain Behav. 2019 Jun;18(5):e12573. doi: 10.1111/gbb.12573. PMID: 30953414.

  21. Roberts BM, Doig NM, Brimblecombe KR, Lopes EF, Siddorn RE, Threlfell S, Connor-Robson N, Bengoa-Vergniory N, Pasternack N, Wade-Martins R, Magill PJ, Cragg SJ (2020): GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model. Nat Commun. 2020 Oct 2;11(1):4958. doi: 10.1038/s41467-020-18247-5. PMID: 33009395; PMCID: PMC7532441.

  22. Farrant M, Nusser Z (2005): Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat Rev Neurosci. 2005 Mar;6(3):215-29. doi: 10.1038/nrn1625. PMID: 15738957.

  23. ((Yu X, Taylor AMW, Nagai J, Golshani P, Evans CJ, Coppola G, Khakh BS (2018): Reducing Astrocyte Calcium Signaling In Vivo Alters Striatal Microcircuits and Causes Repetitive Behavior. Neuron. 2018 Sep 19;99(6):1170-1187.e9. doi: 10.1016/j.neuron.2018.08.015. PMID: 30174118; PMCID: PMC6450394.

  24. Yang P, Cai G, Cai Y, Fei J, Liu G (2013): Gamma aminobutyric acid transporter subtype 1 gene knockout mice: a new model for attention deficit/hyperactivity disorder. Acta Biochim Biophys Sin (Shanghai). 2013 Jul;45(7):578-85. doi: 10.1093/abbs/gmt043. PMID: 23656791.

  25. Chen L, Yang X, Zhou X, Wang C, Gong X, Chen B, Chen Y (2015): Hyperactivity and impaired attention in Gamma aminobutyric acid transporter subtype 1 gene knockout mice. Acta Neuropsychiatr. 2015 Dec;27(6):368-74. doi: 10.1017/neu.2015.37. PMID: 26072958.

  26. Siesser WB, Zhao J, Miller LR, Cheng SY, McDonald MP (2006): Transgenic mice expressing a human mutant beta1 thyroid receptor are hyperactive, impulsive, and inattentive. Genes Brain Behav. 2006 Apr;5(3):282-97. doi: 10.1111/j.1601-183X.2005.00161.x. Erratum in: Genes Brain Behav. 2006 Apr;5(3):298. PMID: 16594981.

  27. Sumitomo A, Saka A, Ueta K, Horike K, Hirai K, Gamo NJ, Hikida T, Nakayama KI, Sawa A, Sakurai T, Tomoda T (2018): Methylphenidate and Guanfacine Ameliorate ADHD-Like Phenotypes in Fez1-Deficient Mice. Mol Neuropsychiatry. 2018 May;3(4):223-233. doi: 10.1159/000488081. PMID: 29888233; PMCID: PMC5981631.

  28. Sakae N, Yamasaki N, Kitaichi K, Fukuda T, Yamada M, Yoshikawa H, Hiranita T, Tatsumi Y, Kira J, Yamamoto T, Miyakawa T, Nakayama KI (2008): Mice lacking the schizophrenia-associated protein FEZ1 manifest hyperactivity and enhanced responsiveness to psychostimulants. Hum Mol Genet. 2008 Oct 15;17(20):3191-203. doi: 10.1093/hmg/ddn215. PMID: 18647754.

  29. Svirin E, de Munter J, Umriukhin A, Sheveleva E, Kalueff AV, Svistunov A, Morozov S, Walitza S, Strekalova T (2022):Aberrant Ganglioside Functions to Underpin Dysregulated Myelination, Insulin Signalling, and Cytokine Expression: Is There a Link and a Room for Therapy? Biomolecules. 2022 Oct 7;12(10):1434. doi: 10.3390/biom12101434. PMID: 36291644; PMCID: PMC9599472. REVIEW

  30. Niimi K, Nishioka C, Miyamoto T, Takahashi E, Miyoshi I, Itakura C, Yamashita T (2011): Impairment of neuropsychological behaviors in ganglioside GM3-knockout mice. Biochem Biophys Res Commun. 2011 Mar 25;406(4):524-8. doi: 10.1016/j.bbrc.2011.02.071. PMID: 21333627.

  31. Yamashita T, Hashiramoto A, Haluzik M, Mizukami H, Beck S, Norton A, Kono M, Tsuji S, Daniotti JL, Werth N, Sandhoff R, Sandhoff K, Proia RL (2003): Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3445-9. doi: 10.1073/pnas.0635898100. PMID: 12629211; PMCID: PMC152312.

  32. Strekalova T, Svirin E, Veniaminova E, Kopeikina E, Veremeyko T, Yung AWY, Proshin A, Walitza S, Anthony DC, Lim LW, Lesch KP, Ponomarev ED (2021): ASD-like behaviors, a dysregulated inflammatory response and decreased expression of PLP1 characterize mice deficient for sialyltransferase ST3GAL5. Brain Behav Immun Health. 2021 Jul 27;16:100306. doi: 10.1016/j.bbih.2021.100306. PMID: 34589798; PMCID: PMC8474501.

  33. Indellicato R, Parini R, Domenighini R, Malagolini N, Iascone M, Gasperini S, Masera N, dall’Olio F, Trinchera M (2019):. Total loss of GM3 synthase activity by a normally processed enzyme in a novel variant and in all ST3GAL5 variants reported to cause a distinct congenital disorder of glycosylation. Glycobiology. 2019 Mar 1;29(3):229-241. doi: 10.1093/glycob/cwy112. PMID: 30576498.

  34. Ohmi Y, Tajima O, Ohkawa Y, Yamauchi Y, Sugiura Y, Furukawa K, Furukawa K (2011): Gangliosides are essential in the protection of inflammation and neurodegeneration via maintenance of lipid rafts: elucidation by a series of ganglioside-deficient mutant mice. J Neurochem. 2011 Mar;116(5):926-35. doi: 10.1111/j.1471-4159.2010.07067.x. Epub 2011 Jan 12. PMID: 21214571.

  35. Shibasaki Y, Hayata-Takano A, Hazama K, Nakazawa T, Shintani N, Kasai A, Nagayasu K, Hashimoto R, Tanida M, Katayama T, Matsuzaki S, Yamada K, Taniike M, Onaka Y, Ago Y, Waschek JA, Köves K, Reglődi D, Tamas A, Matsuda T, Baba A, Hashimoto H (2015): Atomoxetine reverses locomotor hyperactivity, impaired novel object recognition, and prepulse inhibition impairment in mice lacking pituitary adenylate cyclase-activating polypeptide. Neuroscience. 2015 Jun 25;297:95-104. doi: 10.1016/j.neuroscience.2015.03.062. PMID: 25841321.

  36. Rhodes JS, Garland T (2003): Differential sensitivity to acute administration of Ritalin, apomorphine, SCH 23390, but not raclopride in mice selectively bred for hyperactive wheel-running behavior. Psychopharmacology (Berl). 2003 May;167(3):242-50. doi: 10.1007/s00213-003-1399-9. PMID: 12669177.

  37. Rhodes JS, Hosack GR, Girard I, Kelley AE, Mitchell GS, Garland T Jr (2001): Differential sensitivity to acute administration of cocaine, GBR 12909, and fluoxetine in mice selectively bred for hyperactive wheel-running behavior. Psychopharmacology (Berl). 2001 Nov;158(2):120-31. doi: 10.1007/s002130100857. PMID: 11702085.

  38. Oades RD, Sadile AG, Sagvolden T, Viggiano D, Zuddas A, Devoto P, Aase H, Johansen EB, Ruocco LA, Russell VA (2005): The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Dev Sci. 2005 Mar;8(2):122-31. doi: 10.1111/j.1467-7687.2005.00399.x. PMID: 15720370. REVIEW

  39. Sadile AG, Lamberti C, Siegfried B, Welzl H (1993): Circadian activity, nociceptive thresholds, nigrostriatal and mesolimbic dopaminergic activity in the Naples High- and Low-Excitability rat lines. Behav Brain Res. 1993 May 31;55(1):17-27. doi: 10.1016/0166-4328(93)90003-9. PMID: 8101085.

  40. Viggiano D, Vallone D, Welzl H, Sadile AG. The Naples High- and Low-Excitability rats: selective breeding, behavioral profile, morphometry, and molecular biology of the mesocortical dopamine system. Behav Genet. 2002 Sep;32(5):315-33. doi: 10.1023/a:1020210221156. PMID: 12405514. REVIEW

  41. MORTON, J. R. C. (1968) in: FOX, M. W. (Hrsg ) Abnormal Behaviour in Animals. 1. Auflage; W. B. Saunders Company, Philadelphia, London, Toronto: 261-292. Zitiert nach: Maurer, B (2005): Auswirkungen von „Gentling“-Programmen auf das Verhalten von Laborratten (Wistar). Dissertation

  42. Fresiello A, Grammatikopoulos G, Pignatelli M, Sadile AG (2002): Environmental factors during postnatal period modify activity and non-selective attention in the Naples High-Excitability rat. Behav Brain Res. 2002 Mar 10;130(1-2):111-5. doi: 10.1016/s0166-4328(01)00426-0. PMID: 11864726.

  43. Wells, Wimmer, Schmitt, Feng, Halassa (2016): Thalamic reticular impairment underlies attention deficit in Ptchd1Y/− mice. Nature volume532, pages58–63, 07 April 2016

  44. Murakami, Imamura, Saito, Sakai, Motyama (2019): Altered kynurenine pathway metabolites in a mouse model of human attention-deficit hyperactivity/autism spectrum disorders: A potential new biological diagnostic marker. Sci Rep. 2019 Sep 12;9(1):13182. doi: 10.1038/s41598-019-49781-y.

  45. Regan SL, Williams MT, Vorhees CV (2022): Review of rodent models of attention deficit hyperactivity disorder. Neurosci Biobehav Rev. 2022 Jan;132:621-637. doi: 10.1016/j.neubiorev.2021.11.041. PMID: 34848247; PMCID: PMC8816876.) REVIEW

  46. Lou HC (1996): Etiology and pathogenesis of attention-deficit hyperactivity disorder (ADHD): significance of prematurity and perinatal hypoxic-haemodynamic encephalopathy. Acta Paediatr. 1996 Nov;85(11):1266-71. doi: 10.1111/j.1651-2227.1996.tb13909.x. PMID: 8955450. REVIEW

  47. Kumar AJ, Motta-Teixeira LC, Takada SH, Yonamine-Lee V, Machado-Nils AV, Xavier GF, Nogueira MI (2018): Behavioral, cognitive and histological changes following neonatal anoxia: Male and female rats’ differences at adolescent age. Int J Dev Neurosci. 2019 Apr;73:50-58. doi: 10.1016/j.ijdevneu.2018.12.002. Epub 2018 Dec 15. PMID: 30562544.

  48. Ujházy E, Schmidtová M, Dubovický M, Navarova J, Brucknerová I, Mach M (2006): Neurobehavioural changes in rats after neonatal anoxia: effect of antioxidant stobadine pretreatment. Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:82-5. PMID: 17159786.

  49. Rogalska J, Caputa M (2010): Neonatal asphyxia under hyperthermic conditions alters HPA axis function in juvenile rats. Neurosci Lett. 2010 Mar 12;472(1):68-72. doi: 10.1016/j.neulet.2010.01.060. PMID: 20122989.

  50. Dell’Anna ME, Calzolari S, Molinari M, Iuvone L, Calimici R (1991): Neonatal anoxia induces transitory hyperactivity, permanent spatial memory deficits and CA1 cell density reduction in developing rats. Behav Brain Res. 1991 Nov 26;45(2):125-34. doi: 10.1016/s0166-4328(05)80078-6. PMID: 1789921.

  51. Miguel PM, Schuch CP, Rojas JJ, Carletti JV, Deckmann I, Martinato LH, Pires AV, Bizarro L, Pereira LO (2015): Neonatal hypoxia-ischemia induces attention-deficit hyperactivity disorder-like behavior in rats. Behav Neurosci. 2015 Jun;129(3):309-20. doi: 10.1037/bne0000063. PMID: 26030430.

  52. Takada SH, Dos Santos Haemmerle CA, Motta-Teixeira LC, Machado-Nils AV, Lee VY, Takase LF, Cruz-Rizzolo RJ, Kihara AH, Xavier GF, Watanabe IS, Nogueira MI (2015); Neonatal anoxia in rats: hippocampal cellular and subcellular changes related to cell death and spatial memory. Neuroscience. 2015 Jan 22;284:247-259. doi: 10.1016/j.neuroscience.2014.08.054. PMID: 25305666.

  53. Helou AY, Martins DO, Arruda BP, de Souza MC, Cruz-Ochoa NA, Nogueira MI, Chacur M (2021): Neonatal anoxia increases nociceptive response in rats: Sex differences and lumbar spinal cord and insula alterations. Int J Dev Neurosci. 2021 Dec;81(8):686-697. doi: 10.1002/jdn.10145. PMID: 34342028.

  54. Dell’Anna ME, Luthman J, Lindqvist E, Olson L (1993): Development of monoamine systems after neonatal anoxia in rats. Brain Res Bull. 1993;32(2):159-70. doi: 10.1016/0361-9230(93)90070-r. PMID: 8348340.

  55. Kumar AJ, Helou AY, Petrucelli BA, Xavier GF, Martins DO, Chacur M, Nogueira MI (2022): Sensorimotor development of male and female rats subjected to neonatal anoxia. Dev Psychobiol. 2022 Nov;64(7):e22291. doi: 10.1002/dev.22291. PMID: 36282766.

  56. Gross J, Müller I, Chen Y, Elizalde M, Leclere N, Herrera-Marschitz M, Andersson K (2000): Perinatal asphyxia induces region-specific long-term changes in mRNA levels of tyrosine hydroxylase and dopamine D(1) and D(2) receptors in rat brain. Brain Res Mol Brain Res. 2000 Jun 23;79(1-2):110-7. doi: 10.1016/s0169-328x(00)00106-6. PMID: 10925148.

  57. Kohe SE, Gowing EK, Seo S, Oorschot DE (2023): A Novel Rat Model of ADHD-like Hyperactivity/Impulsivity after Delayed Reward Has Selective Loss of Dopaminergic Neurons in the Right Ventral Tegmental Area. Int J Mol Sci. 2023 Jul 8;24(14):11252. doi: 10.3390/ijms241411252. PMID: 37511013; PMCID: PMC10379272.

  58. Liu D, Xie Z, Gu P, Li X, Zhang Y, Wang X, Chen Z, Deng S, Shu Y, Li JD (2023): Cry1Δ11 mutation induces ADHD-like symptoms through hyperactive dopamine D1 receptor signaling. JCI Insight. 2023 Aug 22;8(16):e170434. doi: 10.1172/jci.insight.170434. PMID: 37606043; PMCID: PMC10543712.

  59. Klocke B, Britzolaki A, Saurine J, Ott H, Krone K, Bahamonde K, Thelen C, Tzimas C, Sanoudou D, Kranias EG, Pitychoutis PM (2023): A Novel Role for Phospholamban in the Thalamic Reticular Nucleus. bioRxiv [Preprint]. 2023 Nov 23:2023.11.22.568306. doi: 10.1101/2023.11.22.568306. PMID: 38045420; PMCID: PMC10690257.

  60. González-Martínez Á, Muñiz de Miguel S, Graña N, Costas X, Diéguez FJ (2023): Serotonin and Dopamine Blood Levels in ADHD-Like Dogs. Animals (Basel). 2023 Mar 13;13(6):1037. doi: 10.3390/ani13061037. PMID: 36978578; PMCID: PMC10044280

  61. Anderson (2013): Drugs, dopamine and drosophila — A fly model for ADHD? | David Anderson | TEDxCaltech, Minute 10

  62. Kim, Lee, Han (2007): D1 dopamine receptor dDA1 is required in the mushroom body neurons for aversive and appetitive learning in Drosophila. J Neurosci. 2007 Jul 18;27(29):7640-7. doi: 10.1523/JNEUROSCI.1167-07.2007. PMID: 17634358; PMCID: PMC6672866.

  63. Seugnet, Suzuki, Thimgan, Donlea, Gimbel, Gottschalk, Duntley, Shaw (2009): Identifying sleep regulatory genes using a Drosophila model of insomnia. J Neurosci. 2009 Jun 3;29(22):7148-57. doi: 10.1523/JNEUROSCI.5629-08.2009. PMID: 19494137; PMCID: PMC3654681.

  64. Reiter LT, Potocki L, Chien S, Gribskov M, Bier E (2001): A systematic analysis of human disease-associated gene sequences in Drosophila melanogaster. Genome Res. 2001 Jun;11(6):1114-25. doi: 10.1101/gr.169101. PMID: 11381037; PMCID: PMC311089.

  65. Reichert H (2005): A tripartite organization of the urbilaterian brain: developmental genetic evidence from Drosophila. Brain Res Bull. 2005 Sep 15;66(4-6):491-4. doi: 10.1016/j.brainresbull.2004.11.028. PMID: 16144638.

  66. O’Kane CJ (2011): Drosophila as a model organism for the study of neuropsychiatric disorders. Curr Top Behav Neurosci. 2011;7:37-60. doi: 10.1007/7854_2010_110. PMID: 21225410.

Diese Seite wurde am 18.01.2024 zuletzt aktualisiert.